AbbVie

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AbbVie and other ETFs, options, and stocks.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.

CEO

Richard A. Gonzalez

CEORichard A. Gonzalez

Employees

50,000

Employees50,000

Headquarters

North Chicago, Illinois

HeadquartersNorth Chicago, Illinois

Founded

2011

Founded2011

Employees

50,000

Employees50,000

ABBV Key Statistics

Market cap

286.00B

Market cap286.00B

Price-Earnings ratio

47.86

Price-Earnings ratio47.86

Dividend yield

3.77%

Dividend yield3.77%

Average volume

5.28M

Average volume5.28M

High today

$162.32

High today$162.32

Low today

$160.80

Low today$160.80

Open price

$161.30

Open price$161.30

Volume

278.92K

Volume278.92K

52 Week high

$182.89

52 Week high$182.89

52 Week low

$130.96

52 Week low$130.96

ABBV News

Benzinga 3d

Analyzing AbbVie's Short Interest - AbbVie - Benzinga

Loading... Loading... AbbVie's ABBV short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.54 million share...

Yahoo Finance 4d

Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Yahoo Finance

– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SB...

Quartz 5d

Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.

Every pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar drug that dominates a market, brings in hordes of customers,...

Analyst ratings

59%

of 29 ratings

Buy

58.6%

Hold

41.4%

Sell